2019 American Transplant Congress
Sustained Biologic Response To Neoadjuvant Therapy Predicts Excellent Liver Transplant Outcomes For Locally Advanced Intrahepatic Cholangiocarcinoma
*Purpose: Intrahepatic cholangiocarcinoma (iCCA) is a contraindication for liver transplant (LT), but prior studies limited evaluation to incidental iCCA. We recently reported significant improvement in…2019 American Transplant Congress
Outcomes of Liver Transplantation for Mixed Hepatocellular-Cholangiocarcioma
1Columbia University Medical Center, New York, NY, 2Weill Cornell Medicine, New York, NY
*Purpose: Mixed hepatocholangiocarcinomas (HCC-CCA) are rare tumors with both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) differentiations. They are usually associated with a worse prognosis than…2019 American Transplant Congress
mTOR Inhibitors Enhance Antitumor Activity of Liver Resident NK Cells
Gastroenterology and transplant Surgery, Hiroshima University, Hiroshima, Japan
*Purpose: The immunosuppressive regimen currently used after organ transplantation reduces adaptive components. Therefore, the innate immune cells play pivotal roles in immune surveillance and defense…2019 American Transplant Congress
Tumor Necrosis as a Result to Pre-Transplant Bridging Treatment for Hepatocellular Carcinoma and Its Effect on Post-Transplant Outcome
*Purpose: As a bridge to liver transplantation, locoregional treatments are commonly employed in hepatocellular carcinoma (HCC) patients to prevent tumor progression during waiting time. Objective…2019 American Transplant Congress
Early Everolimus Conversion For Renal Protection In Liver Transplantation: The Sooner The Better?
Henry Ford Health System, Detroit, MI
*Purpose: Calcineurin inhibitors (CNI) are the mainstay of immunosuppressive therapy in transplantation; however, a major side effect limiting CNI use is nephrotoxicity. Mammalian target of…2019 American Transplant Congress
Renal Cell Carcinoma in Dialysis Patients: Criteria for Transplant Wait List Inclusion
*Purpose: End-stage renal disease (ESRD) patients on long-term hemodialysis have a higher incidence of renal cell carcinoma (RCC) in their native kidneys than the general…2018 American Transplant Congress
Predictive Value of mRECIST in HCC Response to the Neoadjuvant Locoregional Therapies and Prognosis Affected by the Peak AFP Level before Liver Transplantation
PURPOSE: The modified response evaluation criteria in solid tumors (mRECIST) has been used to assess the response of hepatocellular carcinoma (HCC) to locoregional therapy (LRT)…2018 American Transplant Congress
Malignancies in Kidney Transplant Recipients: A Long-Term Observational Study
Nephrology and Internal Intensive Care, Charite Universitaetsmedizin Berlin, Berlin, Germany.
Background: Previous studies have shown increased incidence of malignancies in patients after kidney transplantation. However, most of the existing data on post-transplant malignancies is limited…2018 American Transplant Congress
A Novel Nomogram-Based Approach for Defining the Effect of Transplantation on Cancer Recurrence Risk
1U of Cincinnati, Cincinnati; 2Cleveland Clinic, Cleveland.
The effect of transplantation on renal cell cancer (RCC) recurrence risk has not yet been precisely defined. Validated nomograms for predicting RCC recurrence risk (viz,…2018 American Transplant Congress
Liver Transplantation for Patients with Hepatocellular Carcinoma Presenting beyond Milan Criteria: Analysis of 789 Patients from the US Multicenter HCC Transplant Consortium
Objective: OPTN has recently approved MELD prioritization for HCC patients beyond Milan Criteria (MC) who are downstaged (DS) with locoregional therapy (LRT) prior to liver…
American Transplant Congress abstracts